Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2024-09-17 15:42:02 UTC |
---|
NP-MRD ID | NP0000491 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | DL-Dopa |
---|
Description | DL-DOPA, also known as (+-)-DOPA or (R,S)-DOPA or DL-3,4-dihydroxyphenylalanine is an alpha amino acid. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon). DL-DOPA also belongs to the class of organic compounds known as tyrosines and derivatives. Tyrosines and derivatives are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. DL-DOPA is a racemic mixture of both D-DOPA and L-DOPA. D-DOPA is similar to L-DOPA (levodopa), but with opposite chirality. Levo- and dextro- rotation refer to a molecule's ability to rotate planes of polarized light in one or the other direction. Whereas L-DOPA is moderately effective in the treatment of Parkinson's disease (PD) by stimulating the production of dopamine in the brain, D-DOPA was at one time thought to be biologically inactive. However, it has recently been found that D-DOPA can be converted to L-DOPA and then to dopamine via the human enzyme known as D-amino acid oxidase and that racemic mixtures of DL-DOPA can be effective in treating Parkinsonism (PMID: 17924443 ; PMID: 3129126 ; PMID: 17042912 ). The biological production or biosynthesis of D-DOPA is thought to occur through bacterial conversion of tyrosine. L-DOPA is found naturally in both animals and plants. It is made via biosynthesis from the amino acid L-tyrosine by the enzyme tyrosine hydroxylase. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. |
---|
Structure | NC(CC1=CC=C(O)C(O)=C1)C(O)=O InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14) |
---|
Synonyms | Value | Source |
---|
(+-)-3-(3,4-Dihydroxyphenyl)alanine | ChEBI | (+-)-Dopa | ChEBI | (R,S)-Dopa | ChEBI | 3',4'-Dihydroxyphenylalanine | ChEBI | 3-Hydroxy-DL-tyrosine | ChEBI | 3-Hydroxytyrosine | ChEBI | beta-(3,4-Dihydroxyphenyl)-DL-alpha-alanine | ChEBI | DL-3,4-Dopa | ChEBI | DL-beta-(3,4-Dihydroxyphenyl)-alpha-alanine | ChEBI | DL-beta-(3,4-Dihydroxyphenyl)alanine | ChEBI | DL-Dihydroxyphenylalanine | ChEBI | DL-Dioxyphenylalanine | ChEBI | b-(3,4-Dihydroxyphenyl)-DL-a-alanine | Generator | Β-(3,4-dihydroxyphenyl)-DL-α-alanine | Generator | DL-b-(3,4-Dihydroxyphenyl)-a-alanine | Generator | DL-Β-(3,4-dihydroxyphenyl)-α-alanine | Generator | DL-b-(3,4-Dihydroxyphenyl)alanine | Generator | DL-Β-(3,4-dihydroxyphenyl)alanine | Generator | (+/-) 3-(3,4-dihydroxyphenyl)alanine | HMDB | 2-Amino-3-(3,4-dihydroxyphenyl)propanoate | HMDB | 2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid | HMDB | 3,4-Dihydroxy-DL-phenylalanine | HMDB | 3,4-Dihydroxyphenylalanine | HMDB | 3-(3,4-Dihydroxyphenyl)-DL-alanine | HMDB | a-Amino-3,4-dihydroxy-benzenepropanoate | HMDB | a-Amino-3,4-dihydroxy-benzenepropanoic acid | HMDB | alpha-Amino-3,4-dihydroxy-benzenepropanoate | HMDB | alpha-Amino-3,4-dihydroxy-benzenepropanoic acid | HMDB | alpha-Amino-hydrocaffeic acid | HMDB | b-(3,4-Dihydroxyphenyl)-a-alanine | HMDB | beta-(3,4-Dihydroxyphenyl)-alpha-alanine | HMDB | DL-3',4'-Dihydroxyphenylalanine | HMDB | DL-3,4-Dihydroxyphenylalanine | HMDB | DL-3-Hydroxytyrosine | HMDB | DL-4,5-Dihydroxyphenylalanine | HMDB | Dopa | HMDB | 3 Hydroxy DL tyrosine | HMDB | 3,4 Dihydroxyphenylalanine | HMDB | beta-Hydroxytyrosine | HMDB | Dihydroxyphenylalanine hydrochloride, (2:1) | HMDB | beta Hydroxytyrosine | HMDB | Dihydroxyphenylalanine | HMDB |
|
---|
Chemical Formula | C9H11NO4 |
---|
Average Mass | 197.1879 Da |
---|
Monoisotopic Mass | 197.06881 Da |
---|
IUPAC Name | 2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
---|
Traditional Name | 3',4'-dihydroxyphenylalanine |
---|
CAS Registry Number | 63-84-3 |
---|
SMILES | NC(CC1=CC=C(O)C(O)=C1)C(O)=O |
---|
InChI Identifier | InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14) |
---|
InChI Key | WTDRDQBEARUVNC-UHFFFAOYSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Species Where Detected | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tyrosine and derivatives. Tyrosine and derivatives are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Tyrosine and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Tyrosine or derivatives
- Phenylalanine or derivatives
- 3-phenylpropanoic-acid
- Amphetamine or derivatives
- Alpha-amino acid
- Catechol
- 1-hydroxy-2-unsubstituted benzenoid
- 1-hydroxy-4-unsubstituted benzenoid
- Phenol
- Aralkylamine
- Monocyclic benzene moiety
- Benzenoid
- Amino acid
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Hydrocarbon derivative
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Primary aliphatic amine
- Organic nitrogen compound
- Carbonyl group
- Organic oxide
- Organopnictogen compound
- Amine
- Primary amine
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 270 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 3.6 mg/mL | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Goldstein DS, Eisenhofer G, Kopin IJ: Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003 Jun;305(3):800-11. Epub 2003 Mar 20. [PubMed:12649306 ]
- Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F, Lang AE: SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology. 1999 Apr 12;52(6):1206-14. [PubMed:10214745 ]
- Kesten SR, Heffner TG, Johnson SJ, Pugsley TA, Wright JL, Wise LD: Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists. J Med Chem. 1999 Sep 9;42(18):3718-25. [PubMed:10479303 ]
- Furukawa Y, Nygaard TG, Gutlich M, Rajput AH, Pifl C, DiStefano L, Chang LJ, Price K, Shimadzu M, Hornykiewicz O, Haycock JW, Kish SJ: Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology. 1999 Sep 22;53(5):1032-41. [PubMed:10496263 ]
- Preising M, Op de Laak JP, Lorenz B: Deletion in the OA1 gene in a family with congenital X linked nystagmus. Br J Ophthalmol. 2001 Sep;85(9):1098-103. [PubMed:11520764 ]
- Yoshida M, Hirotsu S, Nakahara M, Uchiwa H, Tomita Y: Histamine is involved in ultraviolet B-induced pigmentation of guinea pig skin. J Invest Dermatol. 2002 Feb;118(2):255-60. [PubMed:11841541 ]
- Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, Brooks DJ: Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain. 2002 Jun;125(Pt 6):1358-65. [PubMed:12023324 ]
- Bohme TM, Augelli-Szafran CE, Hallak H, Pugsley T, Serpa K, Schwarz RD: Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors. J Med Chem. 2002 Jul 4;45(14):3094-102. [PubMed:12086495 ]
- Misu Y, Kitahama K, Goshima Y: L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system. Pharmacol Ther. 2003 Feb;97(2):117-37. [PubMed:12559386 ]
- Moore RY, Whone AL, McGowan S, Brooks DJ: Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res. 2003 Aug 29;982(2):137-45. [PubMed:12915249 ]
- Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini PP: Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 2004 Jun;127(Pt 6):1332-42. Epub 2004 Apr 16. [PubMed:15090472 ]
- Moore RT, Chae KA, Rhodes AR: Laugier and Hunziker pigmentation: a lentiginous proliferation of melanocytes. J Am Acad Dermatol. 2004 May;50(5 Suppl):S70-4. [PubMed:15097932 ]
- Sun M, Kong L, Wang X, Holmes C, Gao Q, Zhang GR, Pfeilschifter J, Goldstein DS, Geller AI: Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum Gene Ther. 2004 Dec;15(12):1177-96. [PubMed:15684695 ]
- Pahwa R, Lyons KE, Hauser RA: Ropinirole therapy for Parkinson's disease. Expert Rev Neurother. 2004 Jul;4(4):581-8. [PubMed:15853577 ]
- Mann R, Bhathal PS, Bell C: Sympathetic innervation of the liver in man and dog: an immunohistochemical study. Clin Auton Res. 1991 Jun;1(2):141-5. [PubMed:1688040 ]
- Tohgi H, Abe T, Kikuchi T, Takahashi S, Nozaki Y: The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Neurosci Lett. 1991 Oct 28;132(1):19-22. [PubMed:1787913 ]
- Shigetomi S, Buu NT, Kuchel O: Dopaminergic abnormalities in borderline essential hypertensive patients. Hypertension. 1991 Jun;17(6 Pt 2):997-1002. [PubMed:1904403 ]
- Gill JR Jr, Grossman E, Goldstein DS: High urinary dopa and low urinary dopamine-to-dopa ratio in salt-sensitive hypertension. Hypertension. 1991 Nov;18(5):614-21. [PubMed:1937664 ]
- Rosen CF, Seki Y, Farinelli W, Stern RS, Fitzpatrick TB, Pathak MA, Gange RW: A comparison of the melanocyte response to narrow band UVA and UVB exposure in vivo. J Invest Dermatol. 1987 Jun;88(6):774-9. [PubMed:3108414 ]
- Boomsma F, van der Hoorn FA, Schalekamp MA: Determination of aromatic-L-amino acid decarboxylase in human plasma. Clin Chim Acta. 1986 Sep 15;159(2):173-83. [PubMed:3769207 ]
- Muskiet FA, Fremouw-Ottevangers DC, van der Meulen J, Wolthers BG, de Vries JA: Determination of some L-3,4-dihydroxyphenylalanine and dopamine metabolites in urine by means of mass fragmentography. Clin Chem. 1978 Jan;24(1):122-7. [PubMed:73430 ]
- Eldrup E, Mogensen P, Jacobsen J, Pakkenberg H, Christensen NJ: CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Acta Neurol Scand. 1995 Aug;92(2):116-21. [PubMed:7484057 ]
- Ikeda H, Pastuszko A, Ikegaki N, Kennett RH, Wilson DF: 3,4-dihydroxyphenylalanine (dopa) metabolism and retinoic acid induced differentiation in human neuroblastoma. Neurochem Res. 1994 Dec;19(12):1487-94. [PubMed:7877718 ]
- Cumming P, Gjedde A: Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse. 1998 May;29(1):37-61. [PubMed:9552174 ]
- Kishore A, Nygaard TG, de la Fuente-Fernandez R, Naini AB, Schulzer M, Mak E, Ruth TJ, Calne DB, Snow BJ, Stoessl AJ: Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography. Neurology. 1998 Apr;50(4):1028-32. [PubMed:9566390 ]
- Nakazawa K, Sahuc F, Damour O, Collombel C, Nakazawa H: Regulatory effects of heat on normal human melanocyte growth and melanogenesis: comparative study with UVB. J Invest Dermatol. 1998 Jun;110(6):972-7. [PubMed:9620308 ]
- Kawazoe T, Park HK, Iwana S, Tsuge H, Fukui K: Human D-amino acid oxidase: an update and review. Chem Rec. 2007;7(5):305-15. doi: 10.1002/tcr.20129. [PubMed:17924443 ]
- Karoum F, Freed WJ, Chuang LW, Cannon-Spoor E, Wyatt RJ, Costa E: D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats. Brain Res. 1988 Feb 2;440(1):190-4. doi: 10.1016/0006-8993(88)91176-6. [PubMed:3129126 ]
- Wu M, Zhou XJ, Konno R, Wang YX: D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminase. Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1042-6. doi: 10.1111/j.1440-1681.2006.04484.x. [PubMed:17042912 ]
|
---|